Editor’s note: This is a developing news story. Please check back soon for updates. The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor” designed to produce an anti-inflammatory response and reduce pain. In a phase 2 multicenter, doublemasked, placebo-controlled trial, urcosimod showed statistical significance in endpoints for the treatment of dry eye disease. The

Editor’s note: This is a developing news story. Please check back soon for updates. The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor” designed to produce an anti-inflammatory response and reduce pain. In a phase 2 multicenter, doublemasked, placebo-controlled trial, urcosimod showed statistical significance in endpoints for the treatment of dry eye disease. The